Unavailable
Unavailable
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/3/2025 | Buy → Hold | Berenberg | |
| 4/15/2025 | $35.25 | Neutral | Exane BNP Paribas |
| 2/12/2025 | Equal-Weight | Morgan Stanley | |
| 11/15/2024 | Buy → Hold | Deutsche Bank | |
| 11/12/2024 | $53.00 → $39.50 | Buy → Hold | Jefferies |
| 10/31/2024 | Buy → Neutral | Guggenheim | |
| 7/8/2024 | Buy → Neutral | UBS | |
| 5/30/2024 | $47.00 | Neutral | Goldman |
4 - GLAXOSMITHKLINE PLC (0001131399) (Reporting)
3 - GLAXOSMITHKLINE PLC (0001131399) (Reporting)
4 - GLAXOSMITHKLINE PLC (0001131399) (Reporting)
11-K - GSK plc (0001131399) (Filer)
11-K - GSK plc (0001131399) (Filer)
6-K - GSK plc (0001131399) (Filer)
Berenberg downgraded GlaxoSmithKline from Buy to Hold
Exane BNP Paribas initiated coverage of GlaxoSmithKline with a rating of Neutral and set a new price target of $35.25
Morgan Stanley initiated coverage of GlaxoSmithKline with a rating of Equal-Weight
Grant funding will be provided to support national, state, and local non-profit organizations and community-based groups focused on lupus New resources and tools will support implementation of community-led programs designed to improve earlier diagnosis, enhance awareness of and access to evidence-based treatment, and/or advance communication between patients and providers Deadline for proposals is September 1, 2025 GSK plc (LSE/NYSE:GSK) today announced the launch of the Linked by Lupus: Optimal Care Initiative to help support individuals impacted with lupus, particularly systemic lupus erythematosus (SLE) and lupus nephritis (LN). "Too many people living with lupus face delays
Definitive agreement to result in one-time $225 million cash payment Theravance Biopharma retains rights to up to $150 million in milestones from Royalty Pharma on Trelegy Ellipta net sales in 2025 and 2026, requiring minimal to no growth over 2024 actuals to be achieved$225 million from royalty transaction announced today, in addition to the $1.1 billion upfront received in 2022, and up to $200 million in milestones (of which $50 million was received in 2025), brings total potential lifetime value from Trelegy Ellipta monetization efforts to $1.525 billionFirst outcome from Strategic Review Committee's ongoing efforts to maximize shareholder value; Board remains committed to returning exces
If approved, tebipenem HBr could be the first oral carbapenem antibiotic for US patients with complicated urinary tract infections (cUTIs) An estimated 2.9 million cases of cUTIs are treated annually in the US1 with many cases requiring hospitalization, contributing to over $6 billion per year in healthcare costs2Data from the PIVOT-PO trial to be part of a planned US Food and Drug Administration (FDA) filing in 2H 2025 that Spero's development partner, GSK, intends to submit CAMBRIDGE, Mass., May 28, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO) and GSK plc (LSE/NYSE:GSK), today announced that the pivotal Phase 3 PIVOT-PO trial evaluating tebipenem HBr, an investigation